Today it was reported that a Director at Kindred Biosciences (NASDAQ: KIN), Ernest Mario, exercised options to buy 44,833 KIN shares at $3.41 a share, for a total transaction value of $152.9K.
Following this transaction Ernest Mario’s holding in the company was increased by 55.92% to a total of $2.46 million. Following Ernest Mario’s last KIN Buy transaction on March 17, 2016, the stock climbed by 11.1%.
See today’s analyst top recommended stocks >>
Currently, Kindred Biosciences has an average volume of 569.7K.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $19.00, reflecting a 30.7% upside. Starting in August 2018, KIN received 8 Buy ratings in a row. Three different firms, including B.Riley FBR and Cantor Fitzgerald, currently also have a Buy rating on the stock.
The insider sentiment on Kindred Biosciences has been negative according to 19 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Ernest Mario’s trades have generated a -2.1% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.
